BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for Merger
PALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos
Read morePALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos
Read morePALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos
Read morePALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos
Read morePALO ALTO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on
Read morePALO ALTO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on
Read morePALO ALTO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory
Read moreSAN FRANCISCO, Dec. 23, 2020 (GLOBE NEWSWIRE) — UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced
Read morePALO ALTO, Calif., Dec. 04, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on
Read morePALO ALTO, Calif., Dec. 04, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on
Read moreSAN FRANCISCO, Nov. 13, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Navire Pharma, Inc. announced today
Read more